Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) closed at $170.5 up 0.01% from its previous closing price of $170.48. In other words, the price has increased by $0.01 from its previous closing price. On the day, 0.52 million shares were traded. JAZZ stock price reached its highest trading level at $171.85 during the session, while it also had its lowest trading level at $169.36.
Ratios:
For a deeper understanding of Jazz Pharmaceuticals plc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.06 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.75. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.11.
On July 15, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $152.
UBS Upgraded its Neutral to Buy on March 07, 2025, whereas the target price for the stock was revised from $145 to $179.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 09 ’25 when Henderson Mary Elizabeth sold 2,238 shares for $169.51 per share. The transaction valued at 379,366 led to the insider holds 19,508 shares of the business.
MARY ELIZABETH HENDERSON bought 2,238 shares of JAZZ for $379,365 on Dec 09 ’25. On Dec 05 ’25, another insider, Carr Patricia, who serves as the SVP, Chief Accounting Officer of the company, sold 4,660 shares for $171.20 each. As a result, the insider received 797,783 and left with 7,012 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 10360452096 and an Enterprise Value of 13743342592. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.24. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.49 while its Price-to-Book (P/B) ratio in mrq is 2.62. Its current Enterprise Value per Revenue stands at 3.305 whereas that against EBITDA is 8.547.
Stock Price History:
The Beta on a monthly basis for JAZZ is 0.27, which has changed by 0.384328 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, JAZZ has reached a high of $182.99, while it has fallen to a 52-week low of $95.49. The 50-Day Moving Average of the stock is 8.85%, while the 200-Day Moving Average is calculated to be 33.71%.
Shares Statistics:
For the past three months, JAZZ has traded an average of 1.04M shares per day and 888970 over the past ten days. A total of 60.74M shares are outstanding, with a floating share count of 57.98M. Insiders hold about 4.59% of the company’s shares, while institutions hold 100.47% stake in the company. Shares short for JAZZ as of 1765756800 were 5042462 with a Short Ratio of 4.84, compared to 1763078400 on 4839654. Therefore, it implies a Short% of Shares Outstanding of 5042462 and a Short% of Float of 9.59.
Earnings Estimates
The dynamic stock of Jazz Pharmaceuticals plc (JAZZ) is currently being evaluated by a team of 15.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $4.34, with high estimates of $5.96 and low estimates of $3.52.
Analysts are recommending an EPS of between $8.82 and $7.73 for the fiscal current year, implying an average EPS of $8.1. EPS for the following year is $22.62, with 15.0 analysts recommending between $30.05 and $19.92.
Revenue Estimates
A total of 14 analysts believe the company’s revenue will be $1.16B this quarter.It ranges from a high estimate of $1.22B to a low estimate of $1.11B. As of. The current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $1.09BFor the next quarter, 14 analysts are estimating revenue of $984.62M. There is a high estimate of $1.1B for the next quarter, whereas the lowest estimate is $899M.
A total of 16 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.29B, while the lowest revenue estimate was $4.18B, resulting in an average revenue estimate of $4.23B. In the same quarter a year ago, actual revenue was $4.07BBased on 16 analysts’ estimates, the company’s revenue will be $4.5B in the next fiscal year. The high estimate is $4.73B and the low estimate is $4.12B.
